Showing results (291-300 of 2,409) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|December 22, 2012
Adapting a global cost-effectiveness model to local country requirements: posaconazole case studyGeorge Papadopoulos, Sheena Hunt, Manishi PrasadJournal of Medical Economics|December 11, 2012
Essential medicine policy in China: pros and consShanlian HuJournal of Medical Economics|December 11, 2012
Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burdenJ Fortea, M PriorJournal of Medical Economics|December 11, 2012
Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertensionAaron Waxman, Shih-Yin Chen, Luke Boulanger, et al.Journal of Medical Economics|December 11, 2012
Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the NetherlandsFloortje van Nooten, Sean Stern, Gert-Jan Braunstahl, et al.Journal of Medical Economics|February 28, 2012
Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphineRobert Ikenberg, Nadine Hertel, R Andrew Moore, et al.Journal of Medical Economics|October 1, 2014
Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysisIris Lin, Erik Muser, Michael Munsell, et al.Journal of Medical Economics|June 20, 2013
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agentsStacey Dacosta Byfield, Elaine Yu, Robert Morlock, et al.Journal of Medical Economics|June 20, 2013
Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophreniaKathleen Lang, Victoria Federico, Erik Muser, et al.Journal of Medical Economics|June 20, 2013
Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapyVamsi Bollu, Flavia Ejzykowicz, Krithika Rajagopalan, et al.Pageof 241